Skip to main content

Advertisement

SpringerLink
Log in

Developments in the Field of Myeloma in the Last Decade

  • Review Article
  • Published:
Indian Journal of Hematology and Blood Transfusion Aims and scope Submit manuscript

Abstract

The plasma cell disorders constitute a heterogeneous group of diseases. Accumulation of knowledge in the field has helped us to understand these diseases better, stage them more precisely, prognosticate more accurately and manage them more effectively. The paradigm shift in the management of multiple myeloma over the last one-and-a-half decades shows no signs of slackening. In addition to novel therapies, better supportive care and high-dose melphalan with autologous hematopoietic stem cells have contributed to this positive outcome. This review summarizes the developments in this sphere in the recent past.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kyle RA, Rajkumar SV (2004) Multiple Myeloma. N Engl J Med 351:1860–1873

    Article  CAS  PubMed  Google Scholar 

  2. Palumbo A, Anderson K (2011) Multiple myeloma. N Engl J Med 364:1046–1060

    Article  CAS  PubMed  Google Scholar 

  3. Rajkumar SV, Dimopolos MA, Palumbo A et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538–e548

    Article  PubMed  Google Scholar 

  4. Kumar Shaji, Rajkumar SV, Dispenzieri A et al (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516–2529

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Mateos M-V, Hernandes M-T, Giraldo P et al (2013) Lenalidomide and dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med 369:438–447

    Article  CAS  PubMed  Google Scholar 

  6. Palumbo A, Avet-Loiseau H, Oliva S et al (2015) Revised International staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol 33:2863–2869

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Palumbo A, Bringhen S, Mateos M-V et al (2014) Geriatric assessment predicts survival and toxicities in elderly myeloma: an International Myeloma Working Group report. Blood 125:2068–2074

    Article  Google Scholar 

  8. Kumar S, Paiva B, Anderson KC et al (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17:e328–e346

    Article  PubMed  Google Scholar 

  9. Dimopoulos MA, Sonnevel P, Leung L et al (2010) International Myeloma Working Group recommendation for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol 28:4967–4984

    Article  Google Scholar 

  10. Sonneveld P, Avet-Loiseau H, Lonial S et al (2016) Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 127:2956–2962

    Article  Google Scholar 

  11. Palumbo A, Mina R (2013) Management of older adults with multiple myeloma. Blood Rev 27:133–142

    Article  CAS  PubMed  Google Scholar 

  12. Laorca A, Palumbo A (2015) Optimizing treatment for elderly patients with newly diagnosed multiple myeloma: a personalzed approach. J Cliin Oncol 34:3600–3604

    Article  Google Scholar 

  13. Huilin C, Belch A, Shustil C et al (2016) Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisolone, and thalidomide in the randomized, phase III FIRST trial. J Clin Oncol 34:3609–3617

    Article  Google Scholar 

  14. Mohty M, Harousseau J-L (2014) Treatment of autologous stem cell eligible multiple myeloma patients: ten questions and answers. Haematologica 99:408–416

    Article  PubMed  PubMed Central  Google Scholar 

  15. Moreau P, Attal M, Facon T (2015) Frontline therapy of multiple myeloma. Blood 125:3076–3084

    Article  CAS  PubMed  Google Scholar 

  16. Nooka AK, Karstritis E, Dimopoulos MA, Lonial S (2015) Treatment options for relapsed and refractory multiple myeloma. Blood 125:3085–3099

    Article  CAS  PubMed  Google Scholar 

  17. Laubach J, Garderet L, Mahindra A et al (2016) Management of relapsed multiple myeloma; recommendations of the International Myeloma Working Group. Leukemia 30:1005–1017

    Article  CAS  PubMed  Google Scholar 

  18. Stewart KA, Rajkumar VS, Dimopoulos MA et al (2015) Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372:142–152

    Article  PubMed  Google Scholar 

  19. Shah JJ et al (2015) Carfilzomib, pomalidomide, and dexamethasone for relapsed or efractory myeloma. Blood 126:2284–2290

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Moreau P, Masszi T, Grzasko N et al (2016) Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374:1621–1634

    Article  CAS  PubMed  Google Scholar 

  21. Palumbo A, Chanan-Khan A, Weisel K et al (2016) Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl JMed 375:754–766

    Article  CAS  Google Scholar 

  22. Dimopoulos MA, Oriol A, Nahi H et al (2016) Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 375:1319–1331

    Article  CAS  PubMed  Google Scholar 

  23. Lonial S, Dimopoulos M, Palumbo A et al (2015) Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 373:621–631

    Article  CAS  PubMed  Google Scholar 

  24. Richardson PG, Hungria VTM, Yoon S-S et al (2016) Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma. Blood 127:713–721

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Prince Aly Khan Hospital, Mazagaon, Mumbai, India

    Tapan K. Saikia

Authors
  1. Tapan K. Saikia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tapan K. Saikia.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Saikia, T.K. Developments in the Field of Myeloma in the Last Decade. Indian J Hematol Blood Transfus 33, 3–7 (2017). https://doi.org/10.1007/s12288-017-0777-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12288-017-0777-0

Keywords

Search

Navigation